Novel Therapies in Takayasu Arteritis

Area of Science:

• Immunology
• Rheumatology
• Vascular Medicine

Background:

• Takayasu Arteritis (TAK) is a large-vessel vasculitis affecting the aorta and its branches.
• Cardiac involvement is common and impacts patient prognosis.
• Current treatments, primarily glucocorticoids, carry risks due to long-term use and frequent relapses.

Purpose of the Study:

• To review emerging therapies for Takayasu Arteritis.
• To focus on recent advancements in biologic treatments.
• To analyze the efficacy and safety of these novel approaches.

Main Methods:

• Literature review of recent studies on biologic therapies for TAK.
• Focus on targeted therapies including IL-6 and TNF-α inhibitors.
• Exploration of other agents like JAK-Inhibitors, Rituximab, Ustekinumab, and Abatacept.

Main Results:

• IL-6 and TNF-α pathways are identified as promising therapeutic targets.
• Tocilizumab and TNF inhibitors show emerging efficacy.
• Other biologics like JAK-Inhibitors, Rituximab, Ustekinumab, and Abatacept are under investigation.

Conclusions:

• New biologic therapies offer potential alternatives for refractory TAK or patients intolerant to conventional treatments.
• Targeted approaches focusing on specific inflammatory pathways are advancing TAK management.
• Further research is needed to fully establish the efficacy and safety profiles of these emerging treatments.